Drug Database
Back to search

Germany· DE-A57-7552623d88ecc8e0

Bexaroten Cipla

A bexarotene product containing bexarotene, registered in Germany by Cipla Europe Nv. The same ATC class is registered in 13 of our 19 countries.

ATC L01XF03

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedBexaroten CiplaATCL01XF03REGISTER NO.DE-A57-7552623d88ecc8…PACKS LISTED0CHECKEDSeptember 30, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bexaroteneAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bexarotene is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XF03 (bexarotene), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 8 of them publish a price we can compare per daily dose
Search bexarotene products by name

Bexarotene · ATC L01XF03

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Bexarotene
Manufacturer
Cipla Europe Nv
Country
Germany (DE)
ATC code
L01XF03
ATC class
Bexarotene
Defined daily dose
0.54 g, O
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

573 interactions on record for bexarotene.

Graded by severity as the source publishes them — 127 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bexarotene against other medicinesHow interaction checks work

Bexarotene · interactions on record

573 records

  • 127 severe
  • 357 moderate
  • 80 minor
  • 9 info

Most severe, free to view

  • EluxadolineA07DA06severe
  • LiraglutidA08AX02severe
  • SemaglutidA08AX03severe
  • SitagliptinA10BH01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bexarotene in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bexarotene products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Austria · Bexagia
  • Denmark · Bexarotene
  • Spain · Bexaroteno Cipla
  • Finland · Bexarotene Amdipharm
  • France · Bexarotene Cipla
  • United Kingdom (Northern Ireland) · Bexarotene Genus Pharmaceuticals Ltd.
  • Iceland · Targretin
  • Italy · Bexarotene Cipla
  • Liechtenstein · Targretin
  • Norway · Bexarotene Amdipharm, Targretin
  • Sweden · Bexarotene Amdipharm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4d087b0f-dc6e-41b3-9af7-aff8518c2ebb
GET /v1/drugs/4d087b0f-dc6e-41b3-9af7-aff8518c2ebb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Oral Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Bexarotene",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}
API referenceMCP serverPlans

See everything about bexarotene.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console